These poor prognosis groups include patients with high tumor burden or high lactate dehydrogenase (LDH) levels, uveal melanoma, mucosal melanoma, brain metastases and anti-PD-1 refractory melanoma. Here, PDCD1 is linked to uveal melanoma.